<DOC>
	<DOCNO>NCT00321646</DOCNO>
	<brief_summary>The main purpose trial collect information evaluate effect , good bad , combination docetaxel bevacizumab patient high risk prostate cancer undergo radical prostatectomy .</brief_summary>
	<brief_title>Neoadjuvant Bevacizumab Plus Docetaxel High Risk Patients With Prostate Cancer Undergoing Radical Prostatectomy</brief_title>
	<detailed_description>- Patients eligible study undergo endorectal MRI scan test begin research study . - After MRI , patient begin docetaxel plus bevacizumab part study . Each treatment cycle start day receive drug last 21 day . Patients undergo total 6 cycles-5 docetaxel plus bevacizumab one docetaxel alone . - At begin cycle , patient come clinic visit last 3 hour . The following happen visit : physical examination include vital sign rectal exam ; question patient health medication take ; blood test ( routine research blood test ) ; urine test ; bevacizumab infusion ; docetaxel infusion . - The patient first dose bevacizumab give Day 1 first cycle 90 minute . If patient tolerates 90-minute infusion well , late dos may give short period time . - The day morning begin cycle , patient give steroid call dexamethasone pill form help decrease side effect treatment . - The test procedure repeat every 21 day total five time . For sixth time , patient test procedure except receive bevacizumab . - After six cycle , patient undergo another endorectal MRI . - One two month finish sixth cycle , patient undergo radical prostatectomy remove prostate . - Two three month surgery patient return clinic follow test procedure : question patient 's health ; routine blood test research blood test .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>Histological documentation adenocarcinoma prostate , available biopsy pathology . Material biopsy must available central review DF/HCC begin second cycle therapy . Potential candidate radical prostatectomy Must meet one characteristic : Gleason score 8 , 9 10 ; serum PSA great equal 20 ng/mL ; clinical T stage T3 ; PSA velocity great equal 2ng/mL/year year prior diagnosis ; Gleason score 7 erMRI T3 disease ; Greater equal 50 % total number biopsy core positive prostate cancer either PSA &gt; 10ng/mL Gleason score 7 clinical T stage T2a , T2b T2c . Greater six week since major surgery Serum testosterone &gt; 100ng/dL ECOG Performance Status 0 1 ANC &gt; 1,500/ul Platelets &gt; 100,000/ul Total bilirubin , alkaline phosphatase , AST ALT within normal limit Creatinine &lt; 2.0 x upper limit normal History prior radiation , surgery hormonal therapy treatment prostate cancer Clinical evidence metastatic prostate cancer Ongoing oral steroid use Preexisting neuropathy grade 2 great Severe claustrophobia , inability lie still magnet 60 minute , pacemaker , condition would preclude proximity strong magnet . History follow condition : unstable angina ; symptomatic , clinically significant peripheral vascular disease ; NY Heart Association Grade 2 great heart failure ; uncontrolled hypertension ; myocardial infarction stroke &lt; 12 month prior enrollment ; uncontrolled hypertension ; active , uncontrolled infection ; history DVT , PE know coagulopathy bleeding diathesis ; ongoing u anticoagulant therapy ; history abdominal fistula , GI perforation , intraabdominal abscess within 6 month prior study entry ; nonhealing ulcer fracture ; history another malignancy diagnose within last five year ; spot urine protein : creatinine ratio &gt; 1.0 screening .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>prostate cancer</keyword>
	<keyword>bevacizumab</keyword>
	<keyword>docetaxel</keyword>
	<keyword>radical prostatectomy</keyword>
</DOC>